GU Cancers 2020 | KEYNOTE-921: pembrolizumab + docetaxel & prednisone for mCRPC

VJOncology is committed to improving our service to you

Daniel Petrylak

Daniel Petrylak, MD, Yale Cancer Center, New Haven, CT, discusses the KEYNOTE-921 study (NCT03834506) of pembrolizumab plus docetaxel and prednisone for enzalutamide or abiraterone acetate for patients with metastatic CRPC. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter